Peripheral blood T Regulatory cell counts may not predict transplant rejection by Huang, Yuchuan et al.
Huang et al. BMC Immunology 2010, 11:40
http://www.biomedcentral.com/1471-2172/11/40
Open Access RESEARCH ARTICLE
© 2010 Huang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research article Peripheral blood T Regulatory cell counts may not 
predict transplant rejection
Yuchuan Huang†1,2, Juan Shan†1, Chuntao Zhang1, Jie Zhang1, Li Feng1, Shengfu Li1 and Youping Li*1,3
Abstract
Background: Recent evidence shows that allograft survival rates show a positive correlation with the number of 
circulating T regulatory cells (Tregs). This study investigated both the number and the cytokine profiles exhibited by 
Foxp3+ Tregs in blood, spleen and lymph nodes of Lewis rat recipients of BN rat cardiac allografts after a single-dose of 
Rapamycin (RAPA).
Results: Rats were divided into three groups: control group (containing healthy control and acute rejection group), 
and recipients treated with a single dose of RAPA on either Day 1 (1D group)or Day 3 (3D group) post-transplant. We 
analyzed the number of Foxp3+Tregs and the expression of Foxp3 and cytokines in the peripheral blood and the 
peripheral lymphoid tissues. No difference was found in the numbers of circulating Foxp3+ Tregs between these three 
groups. RAPA administration significantly increased Foxp3 expression in peripheral lymphoid tissues after a single dose 
of RAPA on Day 3 post-transplant. Foxp3+Tregs inhibited the activity of effector T cells (Teff) via the secretion of TGF-β1.
Conclusion: The number of Tregs in the recipient's blood may not be a good predictor of transplant rejection. 
Foxp3+Tregs inhibit the activity of Teff cells mainly in the peripheral lymphoid tissues.
Background
Organ transplantation remains the only solution available
for the treatment of numerous end-stage diseases. The
administration of immunosuppressive drugs following
solid organ transplantation is essential in order to control
the activation of alloreactive T cells and so prevent rejec-
tion of the graft. Although calcineurin inhibitors (CNI),
anti-proliferative agents and steroids all have proven effi-
cacy, immunosuppression after heart transplantation
may still be improved, with respect to increased efficacy
(reduced incidence of acute rejection and chronic
allograft vasculopathy (CAV) and reduced toxicity (less
renal failure and malignancy). The proliferation signal
inhibitor (PSI) Rapamycin (RAPA), and its derivative
everolimus, belong to a new class of potent therapeutic
agents that promise such an improvement. Research has
shown that delayed treatment with RAPA effectively
slows the progression of both allograft rejection [1] and
pre-existing CAV in both rat [2] and non-human primate
grafts [3,4]. Recently, ex vivo studies have shown that, in
both humans and mice, RAPA selectively blocks the pro-
liferation of effector T cells (Teff) while at the same time,
expanding the CD4+CD25+FoxP3+ Treg population [5].
Tregs control various immune responses and play an
important role in inhibiting transplant rejection [6]. It has
been reported that graft survival rates are positively cor-
related with the number of circulating Tregs[7,8], and
that the adoptive transfer of Tregs (polyclonally expanded
in vivo using low-dose RAPA) promotes tolerance to allo-
geneic pancreatic islet grafts [9].
In a retrospective study, Segundo et al[8] found that
RAPA (but not CNI) induces an increase in the number
of circulating Tregs in stable renal transplant recipients.
Therefore, we analyzed both the number and the
cytokine expression levels in Foxp3+ Tregs in the blood,
spleen and lymph nodes of rat transplant recipients after
a single post-operative dose of RAPA. Our data show that
Foxp3+ Tregs inhibit Teff cell activity in the peripheral
lymphoid tissues by secreting cytokines such as TGF-β1.
We also suggest that the number of circulating Tregs may
not be a suitable predictor of transplant rejection.
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Methods
Rats and heart transplantation
Donor male Brown Norway (BN, RT-1n) and Lewis (RT-
11) recipient rats weighing 150-200 g were purchased
from Experimental Animal Centre of West China (Sich-
uan University, Chengdu, China). Rats were divided into
three groups as follows: three rats were used as healthy
controls; nine rats underwent cardiac allograft transplan-
tation with no follow-up treatment (acute rejection (Con)
group); and 24 rats underwent cardiac allograft trans-
plantation followed by a single-dose of RAPA given orally
either 1 day (1D group) or 3 days (3D group) post trans-
plantation. Ethical approval for the work was given by the
University Committee on Use and Care of Laboratory
Animals at Sichuan University.
We used a modified heart abdominal transplantation
[10] and donor hearts were harvested according to the
method of Ono and Lindsey [11]. Briefly, the aortic arch
was ligated between the brachiocephalic trunk and the
left common carotid artery. The vessel was then cut distal
to the ligature. The brachiocephalic trunk was transected,
leaving 2-3 mm attached to the aortic arch. The left pul-
monary artery was ligated and the right pulmonary artery
transected, leaving 2-3 mm attached to pulmonary artery.
The abdomen was then opened by a long midline inci-
sion. The abdominal aorta was clamped proximally and
distally and a 3-0 silk tie looped around both distal vessels
and kept loose. The donor brachiocephalic trunk was
connected end-to-side to the recipient abdominal artery.
When finishing the arterial anastomosis, the silk was tied
and the distal vascular clamp was moved to the proximal
inferior vena cava. The donor right pulmonary artery was
then connected end-to-side to the recipient inferior vena
cava (Fig 1).
Rapamycin treatment and analysis of whole blood RAPA 
concentrations
A single dose of Rapamycin (RAPA; 1 mg/ml, NCPC New
Drug Research and Development Co., Ltd.) was given
intragastrically at 8 mg/kg on either Day 1 (1D group) or
Day 3 (3D group) post-transplantation. Physiological
saline was given to the Con group. At least three indepen-
dent experiments were performed.
Whole-blood trough RAPA concentrations were
dynamically determined using a modified high-perfor-
mance liquid chromatography spectrometry method [12].
Flow Cytometry Analysis
Peripheral Blood samples were taken from the Con group
1, 3 and 6 days after transplantation and from the 1D and
3D groups 1, 3, 7 and 10 days after treatment. The per-
centage of CD3+CD25+Foxp3+ T cells was determined
using three-color flow cytometry. Briefly, lymphocytes
from peripheral blood were collected and suspended in
phosphate-buffered saline (PBS) and then labeled with an
optimal concentration of FITC-conjugated mouse anti-
rat CD3 antibody (G4.18; BD Pharmingen, California,
USA) and Allophycocyanin (APC) anti-rat CD25 (OX-39;
eBioscience, San Diego, USA) in the dark for 30 minutes.
Intracellular staining was performed using a PE anti-
mouse/rat/human Foxp3 Flow Kit (150D, BioLegend, San
Diego, USA). Isotype-matched controls were run concur-
rently.
Immunohistochemistry (IHC)
Hearts, spleens and lymph nodes were harvested from
the Con group 1, 3 and 6 days after transplantation (POD
1, 3, 6) and from the 1D and 3D groups 1, 3, 7 and 10 days
after treatment. Formalin-fixed, paraffin-embedded tis-
sue sections (4-μm) were stained with a 1:100 dilution of
affinity purified anti-muse/rat Foxp3 (FJK-16s, eBiosci-
ence) followed by incubation with the respective biotiny-
lated secondary antibodies. Staining was developed using
an avidin-biotin-based detection system and visualized
with peroxidase or DAB (Dako REAL™ EnVison™ Detec-
tion System, Denmark A/S). The number of stained cells
in each section was counted in 10 ocular grid areas at a
magnification of ×200 and the total was divided by the
number of ocular grid areas.
Figure 1 Modified abdominal heart transplantation model in rat. 
The brachiocephalic trunk (BT) and the right pulmonary artery (RPA) 
were anastomosed to the abdominal artery (AA) and inferior vena ca-
va(IVC) in an end-to-side fashion, respectively.Huang et al. BMC Immunology 2010, 11:40
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RNA preparation and real-time PCR
The levels of Foxp3, IL-10, TGF-β1 and β-actin mRNA
were analyzed by quantitative real-time RT-PCR using a
Light Cycler (Multicolor Real-Time PCR detection sys-
tem). Total RNA isolation and real-time PCR was carried
out according to the manufacturer's instructions. Briefly,
each 20 μl of reaction volume contained 3 mM MgCl2,
Light Cycler Hotstart DAN SYBR Green I Mix, specific
primer pairs, and 5 μl of cDNA. PCR cycling conditions
were 95°C for 3 minutes followed by 45 cycles at 95°C for
15 seconds, 60°C for 15 seconds and 72°C for 15 seconds.
Primers were designed based on the reported cDNA
sequences; the expected fragment sizes for these genes
are specified in Table 1.
Statistical analysis
Student's t-test was used for paired and unpaired analy-
ses. A statistical evaluation for graft survival was per-
formed using the Kaplan-Meier test. p < 0.05 was
considered statistically significant. All experimental data
were representative of three independent experiments.
Results
Effect of delayed RAPA treatment on heart allograft 
survival
The donor heart beat strength was checked on a daily
basis. Untreated Lewis rat recipients of BN heart
allografts had a mean graft survival time of 5.2 ± 1.3 days.
Rats given a single dose of RAPA on either Day 1 or Day 3
post transplant showed significantly prolonged graft sur-
vival times of 11 ± 1.5d (p < 0.05) or 14 ± 2d (p < 0.05),
respectively. Furthermore, the graft survival rate in D3
group was significantly longer than that in D1 group (P <
0.05). We found RAPA was below its effective concentra-
tion (5-15 ng/ml) 5 days after treatment commenced (Fig
2).
Peripheral Blood Treg Counts
We used Flow Cytometry to count the number of circu-
lating CD3+CD25+Foxp3+ Tregs. We were surprised to
find no real differences in the number of circulating
CD3+CD25+Foxp3+  Tregs between the RAPA-treated
group and the normal controls or the acute rejection
group (p > 0.05) (Fig 3 and Fig 4).
Expression levels of Foxp3 differ with time of RAPA 
administration post-transplant
To characterize the Foxp3+ Tregs in the peripheral lym-
phatic organs, we analyzed Foxp3 expression using
immunohistochemistry and real-time PCR. No Foxp3
expression was seen in the rejected heart allografts. The
number of Foxp3+ Tregs increased by Day 1 post-trans-
plant in the spleens compared with normal spleens. From
Day 2 post-transplant, Foxp3+ Treg numbers in the
spleens of the acute rejection group decreased. In the 1D
group, the number of Foxp3 Treg cells in the spleens
decreased on Days 1-3, increased on Days 3-7 and then
decreased again. However, the 3D group showed a differ-
ent pattern. Foxp3 Treg cell numbers showed a peak on
Day 1, decreased on Days 1-3, and peaked again on Day 7
before decreasing again. It is interesting that the time of
RAPA administration post-transplant has different
effects upon Foxp3 expression by the Tregs. It is also
n o t e w o r t h y  t h a t  F o x p 3  e x p r e s s i o n  b y  t h e  T r e g s  w a s
higher in the lymph nodes than in the spleens. (Fig 5,
additional file 1 and 2)
Treg suppression of Teff cell activities
Tregs are fundamental in controlling various immune
responses and many different subsets of Tregs have been
reported. Among these subsets are the induced Tregs
(iTregs) that produce high levels of IL-10 and inhibit Teff
cells[13]. Foxp3+ Tregs also inhibit Teff cells by secreting
TGF-β1/IL-10 [13]. To assess the role of IL-10 and TGF-
β1 in our experiments, real-time PCR was used to exam-
ine the expression of both IL-10 and TGF-β1 mRNA in
recipient Lewis rat spleens. We found that the expression
pattern of TGF-β1 mRNA was the same as that of Foxp3
mRNA (Fig 6). Both displayed a peak on Day 1, decreased
on Days 1-3, and peaked again on Day 7 before decreas-
Table 1: Primers used in this study
Gene Primer annealing temperature
TGF-β1 sense 5'-CTGCTGCCGCTTCTGCTC-3' 56°C
antisense 5'-TGCGCTTCCGTTTCACC-3'
IL-10 sense 5'-CAGACCCACATGCTCCGAGA-3' 51°C
antisense 5'-CAAGGCTTGGCAACCCAAGTA-3'
Foxp3 sense 5'-ACCTCCTCTTCTTCCTTGAACC-3' 56°C
antisense 5'-GCATAAAGTGTGGTCTGTCCTG-3'
GAPDH sense: 5'-CGGCAAGTTCAACTTCACA-3' 56°C
antisense 5'-AAGACGCCAGTAGACTCCACGA-3'Huang et al. BMC Immunology 2010, 11:40
http://www.biomedcentral.com/1471-2172/11/40
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ing again. However, this was not the case for IL-10
mRNA.
Discussion
Recently, it has been shown that RAPA selectively blocks
the proliferation of effector T cells while at the same time
expanding the population of both human and mouse
CD4+CD25+FoxP3+ Tregs ex vivo [1]. In patients trans-
planted with heart [14], lung [15], liver [7] or kidney [8]
grafts, graft survival rates showed a positive correlation
with the number of circulating Tregs. Therefore, in this
study, we monitored the number of circulating
CD3+CD25+Foxp3+ Tregs in the peripheral blood of rats
transplanted with cardiac allografts. We show that RAPA
did not affect the number of circulating Tregs when com-
pared with normal controls, which is in agreement with
the study of Segundo et al[8], but contrary to others. This
conflict may be due to the fact that that several of these
studies compared patients receiving CNI-based immuno-
suppression with those receiving RAPA. Our results
(which include a healthy control group for comparison)
suggest that RAPA has no deleterious effect on Treg
numbers. However, the number of Tregs in patients
treated with CNI appears to be reduced compared with
healthy controls [16]. Therefore, Treg cell numbers in
peripheral blood may not be a suitable predictor for
transplant rejection.
It is known that Foxp3+ nTregs are not only found in
recipient lymphoid tissue after transplantation [17], but
also at the graft site[18]. We hypothesized that lymphoid-
tissue Tregs might be effective at blocking the initiation
of an aggressive response against the graft, whereas at the
graft site they may inhibit the activity of aggressive cells
that have escaped regulation and migrated into the graft
tissue[19]. Therefore, we examined the Foxp3 expression
in both the allograft and lymphoid tissues using IHC and
real-time PCR. We found no Foxp3 expression in the
allograft hearts at the selected time point, but the expres-
sion of Foxp3 mRNA and protein increased significantly
Day 1 post-transplant in the Con group.
We then examined the number of Tregs/CD4+ T cells
in the peripheral blood, spleen, lymph nodes and thymus
of healthy rats using flow cytometry. We found the great-
est number of Tregs in the lymph nodes (3.66 ± 0.84%)
Figure 2 Pharmacokinetics of RAPA in blood samples obtained 
from recipients. The extractions of RAPA from blood samples were in-
jected onto tandem supelcosil C18 columns (Supelco, Bellefonte, PA) 
maintained at 40°C and eluted with mobile phase buffer composed of 
a 90:10 mixture of methanol:water at a flow rate of 0.5 ml/minute. UV 
absorbance was monitored at 276 nm. We found that the concentra-
tion of RAPA was below its effective concentration (5-15 ng/ml) 5 days 
after treatment.
Figure 3 Quantification of Tregs in the peripheral blood of recip-
ient rats. The number of CD3+CD25+Foxp3+ Tregs cells in the blood 
of rats treated with RAPA on Day 1 (1D group)or Day 3 (3 D group) 
post-transplant were compared. Normal subjects (N) and heart trans-
plant recipients without any immunosuppression were used as con-
trols (Con group). No statistically significant difference between the 
groups was found among these three groups. Con group N: Normal 
spleen; POD 1: 1st day after transplantation; POD 3: 3rd days after trans-
plantation; POD6: 6th day after transplantation; 1 D group 1+1d: 1st day 
after RAPA treatment in 1D group; 1+3d: 3rd day after RAPA treatment 
in 1D group; 1+7d: 7th day after RAPA treatment in 1D group; 1+10d: 
10th day after RAPA treatment in 1D group; 3D group 3+1d: 1st day after 
RAPA treatment in 3D group; 3+3d: 3rd day after RAPA treatment in 3D 
group; 3+7d: 7th day after RAPA treatment in 3D group; 3+11d: 11th day 
after RAPA treatment in 3D group.Huang et al. BMC Immunology 2010, 11:40
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followed by spleen (2.24% ± 1.28%), indicating that the
lymph nodes are the major site of Tregs activity.
When a single dose of RAPA was given on Day 3 post
transplantation, Foxp3 expression was increased. This
suggests that lymphoid tissue might be the site where
Tregs suppress activated effector T cells. While, when
RAPA was given on Day 1 post transplantation, Fxop3
expression was decreased. This was conformity with
Wang et al. 1992[1], Poston et al. 1999[2], Ikonen et al.
2000[3] and Dambrin et al.2003[4], which delayed treat-
ment with RAPA effectively slows the progression of both
allograft rejection. Furthermore, RAPA, in clinical treat-
ment, is not traditionally used after transplantation at
once.
The efficacy of RAPA in preventing acute rejection is
known to be related to trough drug levels[20,21]. There-
fore, we assessed the pharmacodynamics of RAPA using
HPLC. We found RAPA was below its effective concen-
tration (5-15 ng/ml) 5 days after treatment (Fig 2). There-
fore, the second peak in Foxp3+ Treg cell numbers seen
in the 3D group at Day 7 may reflect the normal allore-
Figure 4 The rates of CD3+CD25+Foxp3+/CD3+CD25+ in the pe-
ripheral blood of recipient rats. The rates of CD3+CD25+Foxp3+/
CD3+CD25+ in the blood of rats treated with RAPA on Day 1 (1D 
group)or Day 3 (3 D group) post-transplant were compared. Normal 
subjects (N) and heart transplant recipients without any immunosup-
pression were used as controls (Con group). No statistically significant 
difference between the groups was found among these three groups. 
Con group N: Normal spleen; POD 1: 1st day after transplantation; POD 
3: 3rd days after transplantation; POD6: 6th day after transplantation; 1 D 
group 1+1d: 1st day after RAPA treatment in 1D group; 1+3d: 3rd day af-
ter RAPA treatment in 1D group; 1+7d: 7th day after RAPA treatment in 
1D group; 1+10d: 10th day after RAPA treatment in 1D group; 3D group 
3+1d: 1st day after RAPA treatment in 3D group; 3+3d: 3rd day after 
RAPA treatment in 3D group; 3+7d: 7th day after RAPA treatment in 3D 
group; 3+11d: 11th day after RAPA treatment in 3D group.
Figure 5 Time course and localization of Foxp3+ Tregs in spleens 
and lymph nodes assessed by immunohistochemistry. We as-
sessed the dynamic changes in the number of Foxp3+ Tregs in the 
spleens by immunohistochemistry. Tissue sections were stained using 
an anti-Foxp3 monoclonal antibody. The positive cells in the spleens 
were counted in 10 ocular grid areas within each section at a magnifi-
cation of ×200, and total was divided by the number of ocular grid ar-
eas. We counted no less than 6 sections in one time point. We assessed 
the dynamic changes in the numbers of Foxp3+ Tregs in lymph nodes 
(LN) by immunohistochemistry. Tissue sections were stained using an 
anti-Foxp3 monoclonal antibody. The positive cells in spleens were 
counted in 5 ocular grid areas within each section at a magnification of 
×200, and total was divided by the number of ocular grid areas. We 
counted no less than 6 sections in one time point. Con group POD 1: 
1st day after transplantation; POD 3: 3rd days after transplantation; 
POD6: 6th day after transplantation; 1 D group 1+1d: 1st day after RAPA 
treatment in 1D group; 1+3d: 3rd day after RAPA treatment in 1D group; 
1+7d: 7th day after RAPA treatment in 1D group; 1+10d: 10th day after 
RAPA treatment in 1D group; 3D group 3+1d: 1st day after RAPA treat-
ment in 3D group; 3+3d: 3rd day after RAPA treatment in 3D group; 
3+7d: 7th day after RAPA treatment in 3D group; 3+11d: 11th day after 
RAPA treatment in 3D group.Huang et al. BMC Immunology 2010, 11:40
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sponse in the Lewis rat recipients. In addition, the last
treatment time point should be in 5 days.
There are three general modes of suppression (cell con-
tact-dependent suppression, the production of inhibitory
cytokines or the consumption of limiting growth factors)
that may explain the inhibitory actions of Tregs on acti-
vated T cells [22]. It has been proposed that the produc-
tion of inhibitory cytokines[14,23] such as IL-10 and
TGF-β1 play an important role in this suppression. How-
ever, measurements of cytokine concentrations in cell
culture supernatants are typically very low, and picomo-
lar concentrations are unlikely to trigger cellular
responses. Therefore, biologically active cytokine con-
centrations may only be achieved in the microenviron-
ments surrounding the secreting cells. Therefore, we
examined the IL-10 and TGF-β1 mRNA expression by
Tregs both in vivo and in vitro. When RAPA was given on
Day 1 post transplantation, Foxp3 expression was
decreased while IL-10 expression was increased. How-
ever, on Day 3 post transplantation both Foxp3 and TGF-
β1 expression increased, but not that of IL-10 (Fig 6).
These results support the suggestion that there is a role
for cell-surface or secreted TGF-β1 in CD4+CD25+ Treg-
mediated suppression [24-28].
Interestingly, our data show the time of RAPA adminis-
tration has differing effects upon Foxp3 expression and
cytokine secretion by Tregs. As far as we are aware, this is
the first time that this has been reported. We propose
that RAPA administration on Day 1 post-transplant
enhances iTreg proliferation, which then suppresses Teff
cells by secreting IL-10, while RAPA administration on
Day 3 post-transplant increases nTreg proliferation that
in turn, inhibits Teff cells by secreting TGF-β1. The
mechanisms responsible for these effects need further
investigation.
Conclusion
In conclusion, our data indicate that Foxp3+Tregs inhibit
Teff cell activity within the peripheral lymphatic tissues
by secreting cytokines such as TGF-β1. We also show that
the number of circulating Tregs may not be a suitable
predictor of transplant rejection.
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Figure 6 The expression of Foxp3, TGF-β1 and IL-10 mRNA in 
spleens assessed by real-time PCR. Cytokines are known to play an 
important role in immunological regulation by Tregs. Therefore, we 
measured mRNA levels for the inhibitory cytokines, TGF-β1 and IL-10. 
We showed that the dynamic expression profile of TGF-β1 mRNA was 
the same as that of Foxp3 mRNA. This was not the case for IL-10 mRNA. 
Con group N: Normal spleen; POD 1: 1st day after transplantation; POD 
3: 3rd days after transplantation; POD6: 6th day after transplantation; 1 D 
group 1+1d: 1st day after RAPA treatment in 1D group; 1+3d: 3rd day af-
ter RAPA treatment in 1D group; 1+7d: 7th day after RAPA treatment in 
1D group; 1+10d: 10th day after RAPA treatment in 1D group; 3D group 
3+1d: 1st day after RAPA treatment in 3D group; 3+3d: 3rd day after 
RAPA treatment in 3D group; 3+7d: 7th day after RAPA treatment in 3D 
group; 3+11d: 11th day after RAPA treatment in 3D group.Huang et al. BMC Immunology 2010, 11:40
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